Melanoma
News and reporting on melanoma.
Nouscom Closes $72M Series C Funding Round
The firm plans to put the proceeds from the oversubscribed financing toward advancing its off-the-shelf and bespoke neoantigen cancer vaccines.
As Iovance awaits the regulatory fate of lifileucel in refractory melanoma, oncologists touted a subset analysis supporting its standard use in mucosal melanoma.
Liquid biopsy analysis in melanoma patients yields promising avenues for exploring personalized therapy options.
Perspective Therapeutics Treats First Metastatic Melanoma Patient in Radiopharmaceutical Trial
The firm is evaluating its targeted alpha therapy 212Pb-VMT01 in patients whose tumors express MC1R, as determined by a PET imaging agent.
Immatics Begins Phase I/II Trial of IMA402 in HLA-A*02:01-Positive Solid Tumors
The firm is studying the bispecific T-cell redirecting molecule in advanced solid tumors including in patients with melanoma, lung cancer, ovarian cancer, and synovial sarcoma.
Jul 10, 2023
Dec 20, 2022